Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX: RHY), a transformative, predictive cancer diagnostics technology company is pleased to announce the commercial launch of its updated ...

Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — Multimodal circulating tumor DNA blood-based colorectal cancer screening tests may have clinically ...

The US Food and Drug Administration (FDA) approved Exact Sciences' next-generation multitarget stool DNA (mt-sDNA) test, Cologuard Plus, for use in adults 45 or older who are at average risk for ...

A blood-based colorectal cancer (CRC) screening test, SimpleScreen™, has shown a significant leap in performance, ...

Offering a blood test as a secondary option in individuals who previously declined colonoscopy or FIT increased CRC screening by 7.5%. There was no decrease in uptake of first-line screening options.

New blood-based screening tests for colorectal cancer (CRC) offered fewer benefits at higher cost versus other screening options, a cost-effectiveness modeling study suggested. In a comparison against ...

The FDA has approved the Cologuard Plus test, a next-generation, multitarget stool DNA test approved for patients at an average risk for colorectal cancer. The FDA’s approval was based on findings ...

Colorectal cancer (CRC), more commonly called colon cancer, is currently the second-leading cause of cancer-related death in the U.S. But studies find it’s also highly treatable, especially if it’s ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based ...

A look at Exact Sciences Corporation’s acquisition by Abbott: review EXAS revenue growth, margins, and CRC/MRD screening ...

Mark Stenhouse left his executive role at AbbVie to join Exact Sciences because he felt the company was fighting a worthy battle: preventing colorectal cancer. Mr. Stenhouse, now Exact Science’s ...

The first prospective study to evaluate the accuracy of a blood test for people being screened for colorectal cancer (CRC) revealed a high sensitivity and specificity. At 90% specificity, the blood ...